We look forward to partnering with AstraZeneca and MedImmune, leaders in immuno???oncology, in this transforming transaction for Innate Pharma.???The transaction is subject to customary terms and conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and is expected to become effective in the second quarter of 2015.